Jyong Biotech MENS Institutional Ownership

Jyong Biotech Ltd. (NASDAQ:MENS) is held by 19 institutional investors per 13F filings through June 2026.

• These investors held 0.7% of outstanding shares in June 2026, up from 0.6% in March 2026.
• They increased total shares held in Jyong Biotech by 14.87% from the prior quarter, while the number of investors in MENS increased 850.0% year over year.
• Activity in MENS broke down as 10 buyers, 9 sellers, and 0 unchanged among 19 total holders.
• Institutional investors collectively held 488.05K shares in Jyong Biotech as of June 2026, up by 63.2K shares quarter on quarter, and up 465.13K shares year over year.
• BlackRock, Inc. leads ownership in MENS with 260.32K shares as of June 30, 2026, equal to 0.36% of outstanding shares.
• The most significant purchases of MENS for the quarter ending June 2026 came from HRT FINANCIAL LP (38.66K), XTX Topco Ltd (29.07K), RENAISSANCE TECHNOLOGIES LLC (22.9K), State of Wyoming (11.21K), GEODE CAPITAL MANAGEMENT, LLC (4.65K).
• The largest sellers of Jyong Biotech for the quarter ending June 2026 were UBS Group AG (33.32K), Tower Research Capital LLC (TRC) (10.63K), China Universal Asset Management Co., Ltd. (1.07K), Mirae Asset Global Investments Co., Ltd. (472), Jpmorgan Chase & Co (300).
• Per Business Quant data, the top 10 holders of Jyong Biotech for the quarter ending June 2026 are BlackRock, Inc. (260.32K), GEODE CAPITAL MANAGEMENT, LLC (68.88K), HRT FINANCIAL LP (50.42K), XTX Topco Ltd (29.07K), RENAISSANCE TECHNOLOGIES LLC (22.9K), China Universal Asset Management Co., Ltd. (12.1K), State of Wyoming (11.21K), Morgan Stanley (6.11K), Barclays Plc (5.93K), Jpmorgan Chase & Co (5.38K).